News

A new optical coherence tomography (OCT)-based method for IOL power selection has been found to be a promising method for achieving good refractive outcomes when performing cataract surgery in eyes with a history of laser vision correction, according to analyses of data from a retrospective comparative case series.

The FDA has granted 510(k) clearance to Bausch + Lomb’s comprehensive surgical platform-the Stellaris PC Vision Enhancement System-for the integrated 523-nm laser and software.

Alimera Sciences has resubmitted its New Drug Application (NDA) for its fluocinolone acetonide intravitreal implant (Iluvien) to the FDA.

Ophthalmic Women Leaders (OWL) has announced it will honor three award winners during its signature “OWL Monday” reception and program held in conjunction with the American Society of Cataract and Refractive Surgery meeting in Boston.

This month’s simultaneous meeting of the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators will convene in Boston from April 25 to 29.

An array of IOLs under development and in clinical trials show promise for correcting presbyopia or addressing other limitations of existing pseudophakic lenses.

New tools for pediatric glaucoma surgery are becoming available that improve the ability to examine pediatric patients, perform surgeries more easily, and enhance treatment of difficult cases.

Making fun of doctors

Some people say that laughter is the best medicine, whereas others may argue in favor of antibiotics, erectile dysfunction therapies, and medicinal cannabis. Settling arguments about the comparative value of these therapeutic agents is, however, a topic for another day. This editorial seeks to shed light upon the laughter that involves, or is directed at, us physicians.

The American Academy of Ophthalmology (AAO) has officially launched the Intelligent Research in Sight (IRIS) Registry, the United States’ first comprehensive eye disease and condition registry.

Projections on ophthalmology workforce size in the future-as well as growth in patient demand for services-indicates a clear need for more efficient delivery of glaucoma care. Going on the assumption that a tele-ophthalmological approach offers a possible solution, researchers at Johns Hopkins University, Baltimore, undertook a survey to gauge patient acceptance.

Avedro Inc. has received a complete response letter from the FDA regarding the new drug application (NDA) for its riboflavin ophthalmic solution/KXL System.

FDA OKs label update

The FDA has approved a new label update tied to Genentech’s ranibizumab (Lucentis) prescribing information for wet age-related macular degeneration (AMD).